Also, combination therapy of EGFR inhibitors and c-MET inhibitors is a promising way to enhance in vivo and clinical response to targeted therapy in advanced HNSCC, rising new possibility to patients in need of an efficient therapy. The gene discussed is MET; the disease is head and neck squamous cell carcinoma.